Skip to main content

News Releases

Menu
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
November 19, 2014
Initial Data from Ongoing Phase 2 ARIEL2 Study of Rucaparib in Ovarian Cancer Demonstrate Encouraging Clinical Activity and Safety in both BRCA Mutant and BRCAness Patients Download PDF format download (opens in new window)
November 18, 2014
Interim Data from Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling and Durable Clinical Activity and Progression-free Survival (PFS) in Patients with EGFR-Mutant Non-small Cell Lung Cancer (NSCLC) Download PDF format download (opens in new window)
November 17, 2014
Clovis Oncology Enters into Oncology Clinical Trial Collaboration with GlaxoSmithKline Download PDF format download (opens in new window)
November 12, 2014
Clovis Oncology Announces First Patient Enrolled in TIGER-1 Study Download PDF format download (opens in new window)
November 6, 2014
Clovis Oncology Announces Third Quarter 2014 Operating Results Download PDF format download (opens in new window)
November 4, 2014
Clovis Oncology to Present at the 2014 Credit Suisse Healthcare Conference Download PDF format download (opens in new window)
October 23, 2014
Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in Squamous Non-small Cell Lung Cancer Download PDF format download (opens in new window)
October 22, 2014
Clovis Oncology to Announce Third Quarter 2014 Financial Results and Host Webcast Conference Call on November 6 Download PDF format download (opens in new window)
September 28, 2014
Data from Ongoing Phase 2 Studies of Rucaparib in Ovarian Cancer Demonstrate Safety and Clinical Activity, Validate Differentiated Strategy Download PDF format download (opens in new window)
September 10, 2014
Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in FGF-aberrant Advanced Breast Cancer Download PDF format download (opens in new window)
September 9, 2014
Clovis Oncology Announces Exercise in Full by Initial Purchasers of Their Option to Purchase an Additional $37.5 Million Aggregate Principal Amount of the Company’s 2.50% Convertible Senior Notes Due 2021 Download PDF format download (opens in new window)
September 8, 2014
Clovis Oncology to Present at the 2014 Morgan Stanley Global Healthcare Conference Download PDF format download (opens in new window)
September 3, 2014
Clovis Oncology Announces Pricing of $250 Million of Convertible Senior Notes Download PDF format download (opens in new window)
September 2, 2014
Clovis Oncology to Offer $200 Million of Convertible Senior Notes Download PDF format download (opens in new window)
August 7, 2014
Clovis Oncology Announces Second Quarter 2014 Operating Results Download PDF format download (opens in new window)
July 21, 2014
Clovis Oncology to Announce Second Quarter 2014 Financial Results and Host Webcast Conference Call on August 7 Download PDF format download (opens in new window)
June 23, 2014
Clovis Oncology Announces First Patient Enrolled in TIGER2 Study Download PDF format download (opens in new window)
June 16, 2014
Clovis Oncology Announces First Patient Enrolled in RUCAPANC Study Download PDF format download (opens in new window)
May 31, 2014
Clovis Oncology’s CO-1686 Demonstrates Compelling Clinical Activity and Progression-free Survival (PFS) in Updated Phase 1/2 Study Results in Patients with EGFR-Mutant Non-small Cell Lung Cancer (NSCLC) Download PDF format download (opens in new window)
May 31, 2014
Clovis Oncology Announces Encouraging Data from Phase 1/2a Study Evaluating Lucitanib in Advanced Solid Tumors Download PDF format download (opens in new window)
May 31, 2014
Clovis Oncology’s Phase 1 Study of Rucaparib Demonstrates Compelling Clinical Activity and Safety in Patients with Solid Tumors Download PDF format download (opens in new window)
May 19, 2014
Clovis Oncology Receives Breakthrough Therapy Designation for CO-1686 for the Treatment of Second-line EGFR Mutant Non-small Cell Lung Cancer (NSCLC) in Patients with the T790M Mutation Download PDF format download (opens in new window)
May 14, 2014
Clovis Oncology Announces Clinical Data to Be Presented at 2014 ASCO Annual Meeting Download PDF format download (opens in new window)
May 8, 2014
Clovis Oncology Announces First Quarter 2014 Operating Results Download PDF format download (opens in new window)
April 28, 2014
Clovis Oncology to Announce First Quarter 2014 Financial Results and Host Webcast Conference Call on May 8 Download PDF format download (opens in new window)
April 3, 2014
Foundation Medicine and Clovis Oncology Expand Collaboration to Develop Novel Companion Diagnostic for Rucaparib in Ovarian Cancer Download PDF format download (opens in new window)
March 27, 2014
Clovis Oncology’s CO-1686 Demonstrates Compelling Clinical Activity and Progression-free Survival (PFS) in Updated Phase 1 Study Results in Patients with Non-small Cell Lung Cancer (NSCLC) Download PDF format download (opens in new window)
February 27, 2014
Clovis Oncology Announces 2013 Operating Results and Expands CO-1686 Development Program Download PDF format download (opens in new window)
February 18, 2014
Clovis Oncology to Announce Fourth Quarter/Year End 2013 Financial Results and Host Webcast Conference Call on February 27 Download PDF format download (opens in new window)
February 6, 2014
Clovis Oncology to Present at the 2014 Leerink Global Healthcare Conference Download PDF format download (opens in new window)
January 13, 2014
Clovis Oncology Announces 2014 Objectives and Financial Guidance Download PDF format download (opens in new window)
January 6, 2014
Clovis Oncology to Present at the 32nd Annual J.P. Morgan Healthcare Conference Download PDF format download (opens in new window)